Maxim Group Initiates Coverage on Chemomab Therapeutics (NASDAQ:CMMB)

Analysts at Maxim Group initiated coverage on shares of Chemomab Therapeutics (NASDAQ:CMMBGet Free Report) in a research report issued on Monday, MarketBeat reports. The brokerage set a “buy” rating and a $4.00 price target on the stock. Maxim Group’s price objective would indicate a potential upside of 370.59% from the company’s current price.

Separately, Oppenheimer raised Chemomab Therapeutics from a “market perform” rating to an “outperform” rating and set a $6.00 price objective for the company in a report on Monday, May 6th.

Check Out Our Latest Analysis on CMMB

Chemomab Therapeutics Price Performance

Shares of Chemomab Therapeutics stock opened at $0.85 on Monday. The stock has a fifty day moving average price of $0.75 and a 200-day moving average price of $0.64. The firm has a market cap of $9.39 million, a PE ratio of -0.53 and a beta of 0.39. Chemomab Therapeutics has a 1 year low of $0.42 and a 1 year high of $1.89.

Chemomab Therapeutics (NASDAQ:CMMBGet Free Report) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.14. During the same quarter in the prior year, the business posted ($0.72) earnings per share. As a group, equities analysts anticipate that Chemomab Therapeutics will post -0.9 EPS for the current fiscal year.

Chemomab Therapeutics Company Profile

(Get Free Report)

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).

Featured Stories

Receive News & Ratings for Chemomab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemomab Therapeutics and related companies with's FREE daily email newsletter.